Recent Finacing
Recent Raise
Esperance Pharmaceuticals is a clinical‑stage biotech developing targeted anticancer therapeutics using its Cationic Lytic Peptide (CLYP) platform; lead candidate EP‑100 targets LHRH‑receptor‑overexpressing solid tumors in Phase 1.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
